JP6620018B2 - Ｃｒｉｓｐｒに基づくゲノム修飾および制御 - Google Patents

Ｃｒｉｓｐｒに基づくゲノム修飾および制御 Download PDF

Info

Publication number
JP6620018B2
JP6620018B2 JP2015545838A JP2015545838A JP6620018B2 JP 6620018 B2 JP6620018 B2 JP 6620018B2 JP 2015545838 A JP2015545838 A JP 2015545838A JP 2015545838 A JP2015545838 A JP 2015545838A JP 6620018 B2 JP6620018 B2 JP 6620018B2
Authority
JP
Japan
Prior art keywords
rna
sequence
domain
protein
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015545838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502840A (ja
JP2016502840A5 (enExample
Inventor
フチアン・チェン
グレゴリー・ディ・デイビス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Aldrich Co LLC
Original Assignee
Sigma Aldrich Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50883989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6620018(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Aldrich Co LLC filed Critical Sigma Aldrich Co LLC
Publication of JP2016502840A publication Critical patent/JP2016502840A/ja
Publication of JP2016502840A5 publication Critical patent/JP2016502840A5/ja
Application granted granted Critical
Publication of JP6620018B2 publication Critical patent/JP6620018B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015545838A 2012-12-06 2013-12-05 Ｃｒｉｓｐｒに基づくゲノム修飾および制御 Active JP6620018B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261734256P 2012-12-06 2012-12-06
US61/734,256 2012-12-06
US201361758624P 2013-01-30 2013-01-30
US61/758,624 2013-01-30
US201361761046P 2013-02-05 2013-02-05
US61/761,046 2013-02-05
US201361794422P 2013-03-15 2013-03-15
US61/794,422 2013-03-15
PCT/US2013/073307 WO2014089290A1 (en) 2012-12-06 2013-12-05 Crispr-based genome modification and regulation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2017115672A Division JP2017192392A (ja) 2012-12-06 2017-06-13 Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP2018183815A Division JP2019037231A (ja) 2012-12-06 2018-09-28 Ｃｒｉｓｐｒに基づくゲノム修飾および制御

Publications (3)

Publication Number Publication Date
JP2016502840A JP2016502840A (ja) 2016-02-01
JP2016502840A5 JP2016502840A5 (enExample) 2017-01-19
JP6620018B2 true JP6620018B2 (ja) 2019-12-11

Family

ID=50883989

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015545838A Active JP6620018B2 (ja) 2012-12-06 2013-12-05 Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP2017115672A Pending JP2017192392A (ja) 2012-12-06 2017-06-13 Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP2018183815A Pending JP2019037231A (ja) 2012-12-06 2018-09-28 Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP2020074283A Pending JP2020120674A (ja) 2012-12-06 2020-04-17 Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP2021033258A Pending JP2021101706A (ja) 2012-12-06 2021-03-03 Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP2022076698A Active JP7478772B2 (ja) 2012-12-06 2022-05-06 Ｃｒｉｓｐｒに基づくゲノム修飾および制御

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017115672A Pending JP2017192392A (ja) 2012-12-06 2017-06-13 Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP2018183815A Pending JP2019037231A (ja) 2012-12-06 2018-09-28 Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP2020074283A Pending JP2020120674A (ja) 2012-12-06 2020-04-17 Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP2021033258A Pending JP2021101706A (ja) 2012-12-06 2021-03-03 Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP2022076698A Active JP7478772B2 (ja) 2012-12-06 2022-05-06 Ｃｒｉｓｐｒに基づくゲノム修飾および制御

Country Status (16)

Country Link
US (15) US20160017366A1 (enExample)
EP (11) EP3363902B1 (enExample)
JP (6) JP6620018B2 (enExample)
KR (7) KR102243092B1 (enExample)
CN (3) CN105142669B (enExample)
AU (9) AU2013355214B2 (enExample)
BR (1) BR112015012375A2 (enExample)
CA (3) CA2977152C (enExample)
DK (6) DK2928496T3 (enExample)
ES (6) ES2757325T3 (enExample)
IL (5) IL300199B2 (enExample)
LT (4) LT3138910T (enExample)
PL (6) PL3138910T3 (enExample)
PT (6) PT3138911T (enExample)
SG (4) SG11201503824SA (enExample)
WO (1) WO2014089290A1 (enExample)

Families Citing this family (447)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8053191B2 (en) 2006-08-31 2011-11-08 Westend Asset Clearinghouse Company, Llc Iterative nucleic acid assembly using activation of vector-encoded traits
JP6118725B2 (ja) 2010-11-12 2017-04-19 ジェン９・インコーポレイテッドＧｅｎ９，ＩＮＣ． 核酸合成のための方法およびデバイス
EP2637780B1 (en) 2010-11-12 2022-02-09 Gen9, Inc. Protein arrays and methods of using and making the same
MX2013010911A (es) 2011-03-23 2015-03-03 Pioneer Hi Bred Int Metodos para producir un locus de rasgo transgenico complejo.
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
ES2737957T3 (es) 2011-08-26 2020-01-17 Gen9 Inc Composiciones y métodos para el ensamblaje de alta fidelidad de ácidos nucleicos
EP3604555B1 (en) 2011-10-14 2024-12-25 President and Fellows of Harvard College Sequencing by structure assembly
ES2991004T3 (es) 2011-12-22 2024-12-02 Harvard College Métodos para la detección de analitos
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
US9150853B2 (en) 2012-03-21 2015-10-06 Gen9, Inc. Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
CA2871505C (en) 2012-04-24 2021-10-12 Gen9, Inc. Methods for sorting nucleic acids and multiplexed preparative in vitro cloning
CA2869016C (en) 2012-04-25 2020-05-05 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
EP4570908A3 (en) 2012-05-25 2025-10-22 The Regents of the University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
BR112014031891A2 (pt) 2012-06-19 2017-08-01 Univ Minnesota direcionamento genético nas plantas utilizando vírus de dna
IL236303B (en) 2012-06-25 2022-07-01 Gen9 Inc Methods for high-throughput nucleic acid assembly and sequencing
ES2757623T3 (es) * 2012-07-25 2020-04-29 Broad Inst Inc Proteínas de unión a ADN inducibles y herramientas de perturbación genómica y aplicaciones de las mismas
CN116064532A (zh) * 2012-10-23 2023-05-05 基因工具股份有限公司 用于切割靶dna的组合物及其用途
CN105051204B (zh) 2012-11-16 2023-07-21 波赛伊达治疗学股份有限公司 位点特异性酶和使用方法
SG11201503824SA (en) 2012-12-06 2015-06-29 Sigma Aldrich Co Llc Crispr-based genome modification and regulation
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
DK3064585T3 (da) * 2012-12-12 2020-04-27 Broad Inst Inc Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation
PT2784162E (pt) 2012-12-12 2015-08-27 Broad Inst Inc Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
WO2014093622A2 (en) * 2012-12-12 2014-06-19 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
WO2014093595A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
EP2784162B1 (en) 2012-12-12 2015-04-08 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
EP2931892B1 (en) 2012-12-12 2018-09-12 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
IL308158A (en) * 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
JP2016507244A (ja) 2013-02-27 2016-03-10 ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） Ｃａｓ９ヌクレアーゼによる卵母細胞における遺伝子編集
EP3578666A1 (en) 2013-03-12 2019-12-11 President and Fellows of Harvard College Method of generating a three-dimensional nucleic acid containing matrix
EP2971167B1 (en) 2013-03-14 2019-07-31 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
MX376838B (es) * 2013-03-15 2025-03-07 Univ Minnesota Ingenieria genomica de plantas utilizando sistemas crispr/cas.
US20140273230A1 (en) * 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
KR102405549B1 (ko) 2013-03-15 2022-06-08 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
SMT202100516T1 (it) 2013-04-16 2021-11-12 Regeneron Pharma Modificazione mirata del genoma di ratto
WO2014172470A2 (en) * 2013-04-16 2014-10-23 Whitehead Institute For Biomedical Research Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
US9873894B2 (en) * 2013-05-15 2018-01-23 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
JP7065564B2 (ja) * 2013-05-29 2022-05-12 セレクティス Ｃａｓ９ニッカーゼ活性を用いて正確なｄｎａ切断をもたらすための方法
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
SG10201913068PA (en) * 2013-06-04 2020-02-27 Harvard College Rna-guided transcriptional regulation
JP7085716B2 (ja) * 2013-06-05 2022-06-17 デューク ユニバーシティ Ｒｎａガイド遺伝子編集及び遺伝子調節
WO2014199358A1 (en) 2013-06-14 2014-12-18 Cellectis Methods for non-transgenic genome editing in plants
AU2014281026B2 (en) 2013-06-17 2020-05-28 Massachusetts Institute Of Technology Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
KR20160019553A (ko) * 2013-06-17 2016-02-19 더 브로드 인스티튜트, 인코퍼레이티드 유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
WO2014204729A1 (en) * 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
EP3725885A1 (en) 2013-06-17 2020-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
WO2014204725A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
RU2716420C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
WO2015006294A2 (en) * 2013-07-10 2015-01-15 President And Fellows Of Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
MX363842B (es) 2013-08-22 2019-04-05 Du Pont Métodos para producir modificaciones genéticas en un genoma vegetal sin incorporar un marcador transgénico seleccionable, y composiciones de éstas.
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
TW201542816A (zh) 2013-09-18 2015-11-16 Kymab Ltd 方法、細胞與生物體
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
ES2670983T3 (es) 2013-11-07 2018-06-04 Editas Medicine, Inc. Métodos y composiciones relacionados con CRISPR con ARNg rectores
BR112016013400B1 (pt) 2013-12-11 2023-02-14 Regeneron Pharmaceuticals, Inc. Método in vitro para modificar um genoma em um lócus genômico de interesse em uma célula pluripotente
EP3080279B1 (en) 2013-12-11 2018-09-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
WO2015089473A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
CA2932436A1 (en) 2013-12-12 2015-06-18 The Broad Institute, Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
CA2932478A1 (en) 2013-12-12 2015-06-18 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
EP3080271B1 (en) 2013-12-12 2020-02-12 The Broad Institute, Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
CA2932439A1 (en) 2013-12-12 2015-06-18 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
WO2015089465A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
US10787654B2 (en) * 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
MX375420B (es) 2014-02-11 2025-03-06 Univ Colorado Regents Ingenieria genetica multiplexada habilitada por crispr.
US10286084B2 (en) 2014-02-18 2019-05-14 Duke University Compositions for the inactivation of virus replication and methods of making and using the same
EP3114227B1 (en) 2014-03-05 2021-07-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015138510A1 (en) 2014-03-10 2015-09-17 Editas Medicine., Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
AU2015236128A1 (en) * 2014-03-25 2016-11-10 Editas Medicine Inc. CRISPR/CAS-related methods and compositions for treating HIV infection and AIDS
EP3981876A1 (en) 2014-03-26 2022-04-13 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
WO2015153780A1 (en) 2014-04-02 2015-10-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating primary open angle glaucoma
EP3129490A4 (en) 2014-04-08 2017-10-04 North Carolina State University Methods and compositions for rna-directed repression of transcription using crispr-associated genes
MX2016014066A (es) 2014-04-28 2017-05-03 Recombinetics Inc Edicion de genes multiples en cerdos.
US9970001B2 (en) 2014-06-05 2018-05-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease design
RS60359B1 (sr) 2014-06-06 2020-07-31 Regeneron Pharma Postupci i kompozicije za modifikovanje ciljanog lokusa
WO2015195621A1 (en) * 2014-06-16 2015-12-23 The Johns Hopkins University Compositions and methods for the expression of crispr guide rnas using the h1 promoter
AU2015277180A1 (en) * 2014-06-17 2017-01-12 Poseida Therapeutics, Inc. A method for directing proteins to specific loci in the genome and uses thereof
MX379237B (es) * 2014-06-23 2025-03-10 Regeneron Pharma Ensamblaje de adn mediado por nucleasa.
WO2015200805A2 (en) 2014-06-26 2015-12-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
EP3167071B1 (en) * 2014-07-09 2020-10-07 Gen9, Inc. Compositions and methods for site-directed dna nicking and cleaving
US10179932B2 (en) 2014-07-11 2019-01-15 President And Fellows Of Harvard College Methods for high-throughput labelling and detection of biological features in situ using microscopy
WO2016011080A2 (en) * 2014-07-14 2016-01-21 The Regents Of The University Of California Crispr/cas transcriptional modulation
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
KR20180015731A (ko) * 2014-08-06 2018-02-13 주식회사 툴젠 캄필로박터 제주니 crispr/cas 시스템 유래 rgen을 이용한 유전체 교정
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
US10570418B2 (en) 2014-09-02 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification
CA2956487A1 (en) 2014-09-12 2016-03-17 E. I. Du Pont De Nemours And Company Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
US9879283B2 (en) * 2014-10-09 2018-01-30 Life Technologies Corporation CRISPR oligonucleotides and gene editing
EP3204399B1 (en) * 2014-10-09 2025-01-22 Seattle Children's Hospital, dba Seattle Children's Research Institute Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
CN107002042A (zh) 2014-10-15 2017-08-01 瑞泽恩制药公司 用于产生或维持多能细胞的方法和组合物
US20170306306A1 (en) * 2014-10-24 2017-10-26 Life Technologies Corporation Compositions and Methods for Enhancing Homologous Recombination
GB201418965D0 (enExample) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
WO2016070037A2 (en) * 2014-10-31 2016-05-06 Massachusetts Institute Of Technology Massively parallel combinatorial genetics for crispr
EP3215611B1 (en) * 2014-11-06 2019-08-21 E. I. du Pont de Nemours and Company Peptide-mediated delivery of rna-guided endonuclease into cells
CA2963820A1 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
US20170369848A1 (en) * 2014-11-11 2017-12-28 Q Therapeutics, Inc. Engineering mesenchymal stem cells using homologous recombination
CN107109422B (zh) * 2014-11-19 2021-08-13 基础科学研究院 使用由两个载体表达的拆分的Cas9的基因组编辑
MX389266B (es) 2014-11-21 2025-03-20 Regeneron Pharma Metodos y composiciones para la modificacion genetica dirigida mediante el uso de arn guia combinados.
GB201421096D0 (en) 2014-11-27 2015-01-14 Imp Innovations Ltd Genome editing methods
CN107250148B (zh) 2014-12-03 2021-04-16 安捷伦科技有限公司 具有化学修饰的指导rna
JP6830437B2 (ja) 2014-12-10 2021-02-17 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 疾患を処置するための遺伝子改変された細胞、組織および臓器
EP3230451B1 (en) 2014-12-12 2021-04-07 The Broad Institute, Inc. Protected guide rnas (pgrnas)
JP2017538427A (ja) * 2014-12-18 2017-12-28 インテグレイテッド ディーエヌエイ テクノロジーズ インコーポレイテッド Ｃｒｉｓｐｒ系組成物及び使用方法
SG11201704646YA (en) 2014-12-19 2017-07-28 Regeneron Pharma Methods and compositions for targeted genetic modification through single-step multiple targeting
EP3234111A1 (en) 2014-12-19 2017-10-25 Regeneron Pharmaceuticals, Inc. Stem cells for modeling type 2 diabetes
EP3702456A1 (en) 2014-12-24 2020-09-02 The Broad Institute, Inc. Crispr having or associated with destabilization domains
EP3250688B1 (fr) 2015-01-29 2021-07-28 Meiogenix Procede pour induire des recombinaisons meiotiques ciblees
EP3256487A4 (en) 2015-02-09 2018-07-18 Duke University Compositions and methods for epigenome editing
CN114231527A (zh) 2015-04-06 2022-03-25 里兰斯坦福初级大学理事会 用于crispr/cas介导的基因调控的化学修饰的引导rna
US11180793B2 (en) 2015-04-24 2021-11-23 Editas Medicine, Inc. Evaluation of Cas9 molecule/guide RNA molecule complexes
US20180156807A1 (en) 2015-04-29 2018-06-07 New York University Method for treating high-grade gliomas
US11845928B2 (en) 2015-05-04 2023-12-19 Tsinghua University Methods and kits for fragmenting DNA
US11390884B2 (en) 2015-05-11 2022-07-19 Editas Medicine, Inc. Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
SG10202112057QA (en) * 2015-05-12 2021-12-30 Sangamo Therapeutics Inc Nuclease-mediated regulation of gene expression
AU2016270649B2 (en) 2015-05-29 2022-04-21 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
WO2016196887A1 (en) 2015-06-03 2016-12-08 Board Of Regents Of The University Of Nebraska Dna editing using single-stranded dna
CN116334142A (zh) 2015-06-09 2023-06-27 爱迪塔斯医药公司 用于改善移植的crispr/cas相关方法和组合物
KR102902492B1 (ko) 2015-06-15 2025-12-18 노쓰 캐롤라이나 스테이트 유니버시티 핵산 및 rna-기반 항미생물제를 효율적으로 전달하기 위한 방법 및 조성물
JP2018521689A (ja) * 2015-06-17 2018-08-09 ポセイダ セラピューティクス， インコーポレイテッド タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
CA2989830A1 (en) 2015-06-18 2016-12-22 The Broad Institute, Inc. Crispr enzyme mutations reducing off-target effects
WO2016210271A1 (en) * 2015-06-24 2016-12-29 Sigma-Aldrich Co. Llc Cell cycle dependent genome regulation and modification
IL257105B (en) 2015-07-31 2022-09-01 Univ Minnesota Modified cells and methods of therapy
EP3334746B1 (en) 2015-08-14 2021-11-24 The University Of Sydney Connexin 45 inhibition for therapy
EP4345455A3 (en) 2015-08-25 2024-07-17 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
HK1257676A1 (zh) 2015-08-28 2019-10-25 The General Hospital Corporation 工程化 crispr-cas 9 核酸酶
WO2017053879A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
KR101795999B1 (ko) 2015-09-25 2017-11-09 전남대학교산학협력단 Crispr/cas9 시스템을 이용한 베타2-마이크로글로불린 유전자 제거용 시발체
KR101745863B1 (ko) 2015-09-25 2017-06-12 전남대학교산학협력단 Crispr/cas9 시스템을 이용한 프로히비틴2 유전자 제거용 시발체
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
EP4089175A1 (en) * 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
RU2695636C1 (ru) 2015-10-22 2019-07-25 Телефонактиеболагет Лм Эрикссон (Пабл) Способы и устройство, имеющие отношение к выборочному повышению уровня радиосигналов
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and uses thereof
EP3368054A4 (en) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
WO2017079406A1 (en) 2015-11-03 2017-05-11 President And Fellows Of Harvard College Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
US11905521B2 (en) 2015-11-17 2024-02-20 The Chinese University Of Hong Kong Methods and systems for targeted gene manipulation
US10240145B2 (en) * 2015-11-25 2019-03-26 The Board Of Trustees Of The Leland Stanford Junior University CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
CN108779466B (zh) 2015-11-30 2024-03-29 杜克大学 用于通过基因编辑修正人肌营养不良蛋白基因的治疗靶标和使用方法
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
BR112018013679A2 (pt) 2016-01-11 2019-01-22 Univ Leland Stanford Junior proteínas quiméricas e métodos de regulação de expressão gênica
JP7012645B2 (ja) 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
WO2017165862A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
WO2017180694A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Cas9 fusion molecules gene editing systems, and methods of use thereof
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
EP3443085B1 (en) * 2016-04-14 2022-09-14 BOCO Silicon Valley, Inc. Genome editing of human neural stem cells using nucleases
JP7148494B2 (ja) * 2016-04-25 2022-10-05 ウニベルシテート バーゼル アレル編集およびその応用
WO2017189525A1 (en) 2016-04-25 2017-11-02 President And Fellows Of Harvard College Hybridization chain reaction methods for in situ molecular detection
JP2019517788A (ja) * 2016-05-06 2019-06-27 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作された細胞および同細胞を作製する方法
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
BR112018074531B1 (pt) * 2016-06-02 2021-01-19 Sigma-Aldrich Co. Llc composição que compreende um sistema de nuclease e seu uso, kit, método in vitro para aumentar a eficiência da modificação do genoma-alvo e método para detectar uma sequência cromossômica
RU2018144877A (ru) * 2016-06-03 2020-07-09 Темпл Юниверсити - Оф Де Коммонвелт Систем Оф Хаер Эдьюкейшн Регуляция HIV-1 по механизму отрицательной обратной связи с помощью стратегии редактирования генов
AU2017275769B2 (en) * 2016-06-03 2023-04-13 Assistance Publique - Hôpitaux De Paris Diet controlled expression of a nucleic acid encoding Cas9 nuclease and uses thereof
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
US10337051B2 (en) 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
JP2019518478A (ja) 2016-06-24 2019-07-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ バーコードを付けたコンビナトリアルライブラリーを生成する方法
WO2018013720A1 (en) * 2016-07-12 2018-01-18 Washington University Incorporation of internal polya-encoded poly-lysine sequence tags and their variations for the tunable control of protein synthesis in bacterial and eukaryotic cells
WO2018017754A1 (en) 2016-07-19 2018-01-25 Duke University Therapeutic applications of cpf1-based genome editing
CA3032124A1 (en) 2016-07-28 2018-02-01 Regeneron Pharmaceuticals, Inc. Gpr156 variants and uses thereof
SG11201901305YA (en) 2016-07-29 2019-03-28 Regeneron Pharma Mice comprising mutations resulting in expression of c-truncated fibrillin-1
WO2018026976A1 (en) 2016-08-02 2018-02-08 Editas Medicine, Inc. Compositions and methods for treating cep290 associated disease
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US11078481B1 (en) 2016-08-03 2021-08-03 KSQ Therapeutics, Inc. Methods for screening for cancer targets
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
US20190185850A1 (en) * 2016-08-20 2019-06-20 Avellino Lab Usa, Inc. Single guide rna/crispr/cas9 systems, and methods of use thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11078483B1 (en) 2016-09-02 2021-08-03 KSQ Therapeutics, Inc. Methods for measuring and improving CRISPR reagent function
US20180105806A1 (en) * 2016-09-07 2018-04-19 Massachusetts Institute Of Technology Method for rna-guided endonuclease-based dna assembly
CN106636197B (zh) * 2016-09-22 2019-09-03 南京市妇幼保健院 一种定向敲降斑马鱼基因组中多拷贝基因的方法
US20190225974A1 (en) 2016-09-23 2019-07-25 BASF Agricultural Solutions Seed US LLC Targeted genome optimization in plants
EA201990860A1 (ru) 2016-09-30 2019-10-31 Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
EA201990861A1 (ru) * 2016-09-30 2019-09-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
WO2018071572A1 (en) * 2016-10-11 2018-04-19 Stemgenics, Inc. Nanoparticles functionalized with gene editing tools and related methods
JP7399710B2 (ja) 2016-10-14 2023-12-18 ザ ジェネラル ホスピタル コーポレイション エピジェネティックに調節される部位特異的ヌクレアーゼ
CN110214180A (zh) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 核碱基编辑器的aav递送
GB201617559D0 (en) 2016-10-17 2016-11-30 University Court Of The University Of Edinburgh The Swine comprising modified cd163 and associated methods
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
SG11201903454VA (en) * 2016-11-02 2019-05-30 Univ Basel Immunologically discernible cell surface variants for use in cell therapy
EP3555297A1 (en) 2016-12-19 2019-10-23 Editas Medicine, Inc. Assessing nuclease cleavage
KR102551664B1 (ko) * 2016-12-22 2023-07-05 인텔리아 테라퓨틱스, 인크. 알파-1 항트립신 결핍을 치료하기 위한 조성물 및 방법
US20200385753A1 (en) * 2016-12-23 2020-12-10 Institute For Basic Science Composition for base editing for animal embryo and base editing method
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11859219B1 (en) 2016-12-30 2024-01-02 Flagship Pioneering Innovations V, Inc. Methods of altering a target nucleotide sequence with an RNA-guided nuclease and a single guide RNA
WO2018129368A2 (en) 2017-01-06 2018-07-12 Editas Medicine, Inc. Methods of assessing nuclease cleavage
IL268156B2 (en) 2017-01-23 2025-01-01 Regeneron Pharma Variants of 17-beta-hydroxysteroid dehydrogenase and their uses
WO2018140497A1 (en) 2017-01-25 2018-08-02 Efimov Igor R Apparatus and methods for in vitro preclinical human trials
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
CN106978438B (zh) * 2017-02-27 2020-08-28 北京大北农生物技术有限公司 提高同源重组效率的方法
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US11913015B2 (en) 2017-04-17 2024-02-27 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
US11834670B2 (en) 2017-04-19 2023-12-05 Global Life Sciences Solutions Usa Llc Site-specific DNA modification using a donor DNA repair template having tandem repeat sequences
CN111031790A (zh) 2017-04-20 2020-04-17 E开创生物技术股份有限公司 产生基因修改的动物的方法
WO2018195545A2 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
WO2018201086A1 (en) 2017-04-28 2018-11-01 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CA3063449A1 (en) 2017-05-25 2018-11-29 The General Hospital Corporation Using split deaminases to limit unwanted off-target base editor deamination
MX2019014661A (es) 2017-06-05 2020-07-29 Regeneron Pharma Variantes de b4galt1 y usos de estas.
KR102746733B1 (ko) 2017-06-09 2024-12-24 에디타스 메디신, 인코포레이티드 조작된 cas9 뉴클레아제
KR20240027153A (ko) 2017-06-15 2024-02-29 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 비-바이러스 dna 삽입
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
JP7278978B2 (ja) 2017-06-27 2023-05-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ａｓｇｒ１座位を含む非ヒト動物
AU2018291041B2 (en) 2017-06-30 2021-08-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
US10604752B2 (en) 2017-07-11 2020-03-31 Sigma-Aldrich Co. Llc Using nucleosome interacting protein domains to enhance targeted genome modification
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
KR102780441B1 (ko) 2017-07-31 2025-03-17 리제너론 파마슈티칼스 인코포레이티드 Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도
BR112020001996A2 (pt) 2017-07-31 2020-08-18 Regeneron Pharmaceuticals, Inc. animal não humano, e, métodos para testar e para otimizar a capacidade de uma crispr/cas nuclease de excisar um ácido nucleico genômico in vivo, para testar a recombinação induzida por crispr/cas de um ácido nucleico genômico com um ácido nucleico de doador exógeno in vivo e para otimizar a capacidade de crispr/cas de induzir a recombinação de um ácido nucleico genômico com um ácido nucleico de doador exógeno in vivo.
US20190032053A1 (en) * 2017-07-31 2019-01-31 Sigma-Aldrich Co. Llc Synthetic guide rna for crispr/cas activator systems
CN110891419A (zh) 2017-07-31 2020-03-17 瑞泽恩制药公司 评价crispr/cas-诱导的与外源供体核酸的体内重组
EP3665279B1 (en) * 2017-08-09 2023-07-19 Benson Hill, Inc. Compositions and methods for modifying genomes
US10738327B2 (en) 2017-08-28 2020-08-11 Inscripta, Inc. Electroporation cuvettes for automation
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US12404505B2 (en) 2017-09-05 2025-09-02 Regeneron Pharmaceuticals, Inc. Delivery of a gene-editing system with a single retroviral particle and methods of generation and use
FI3679158T3 (fi) 2017-09-06 2025-06-18 Regeneron Pharma Yksittäisimmunoglobuliini-interleukiini-1-reseptoriin liittyvän proteiinin (SIGIRR) variantteja ja niiden käyttöjä
MX2020002644A (es) 2017-09-07 2020-10-07 Regeneron Pharma Variantes del miembro 1 de la familia 14 del grupo portador de solutos (slc14a1) y usos de estas.
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
AU2018338990B2 (en) 2017-09-30 2022-06-23 Inscripta, Inc. Flow through electroporation instrumentation
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
US11634716B2 (en) 2017-10-16 2023-04-25 University of Pittsburgh—of the Commonwealth System of Higher Education Genetically modified mesenchymal stem cells for use in cardiovascular prosthetics
RU2020115869A (ru) 2017-10-16 2021-11-19 Ридженерон Фармасьютикалз, Инк. Варианты корнулина (crnn) и их применение
MY201694A (en) 2017-10-27 2024-03-13 Univ California Targeted replacement of endogenous t cell receptors
AU2018358051B2 (en) 2017-11-01 2025-01-09 The Regents Of The University Of California CasZ compositions and methods of use
US12227753B2 (en) 2017-11-01 2025-02-18 The Regents Of The University Of California CasY compositions and methods of use
WO2019089808A1 (en) 2017-11-01 2019-05-09 The Regents Of The University Of California Class 2 crispr/cas compositions and methods of use
BR112020008627A2 (pt) 2017-11-03 2020-12-22 University Of Florida Research Foundation, Inc. Métodos e composições para resistência a patógenos de plantas em plantas
CA3076371C (en) 2017-11-10 2022-11-22 Regeneron Pharmaceuticals, Inc. Non-human animals comprising slc30a8 mutation and methods of use
WO2019099943A1 (en) * 2017-11-16 2019-05-23 Astrazeneca Ab Compositions and methods for improving the efficacy of cas9-based knock-in strategies
CN111655031B (zh) 2017-11-30 2022-11-18 瑞泽恩制药公司 包含人源化trkb基因座的非人动物
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
WO2019126578A1 (en) * 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
KR20210152597A (ko) * 2017-12-22 2021-12-15 (주)지플러스생명과학 키메라 게놈 조작 분자 및 방법
BR112020014168A2 (pt) 2018-01-12 2020-12-08 Basf Se Proteína, ácido nucleico isolado, gene recombinante, vetor, célula hospedeira, planta, parte de planta ou semente de trigo, métodos para produzir, produto de trigo, farinha, farelo integral, amido, grânulos de amido ou farelo de trigo e métodos para identificar e/ou selecionar uma planta de trigo
EP3740580A4 (en) 2018-01-19 2021-10-20 Duke University GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS
EP3743516A4 (en) * 2018-01-26 2021-10-13 The Children's Medical Center Corporation TARGETING OF DISTAL BCL11A REGULATORY ELEMENTS WITH A CAS9-CAS9 FUSION TO REDUCE FETAL HEMOGLOBIN
WO2019161290A1 (en) * 2018-02-15 2019-08-22 Sigma-Aldrich Co. Llc Engineered cas9 systems for eukaryotic genome modification
US12084676B2 (en) 2018-02-23 2024-09-10 Pioneer Hi-Bred International, Inc. Cas9 orthologs
CA3093702A1 (en) 2018-03-14 2019-09-19 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
CN116349651A (zh) 2018-03-19 2023-06-30 瑞泽恩制药公司 使用crispr/cas系统对动物进行转录调制
EP3775159A4 (en) 2018-03-29 2022-01-19 Inscripta, Inc. AUTOMATED REGULATION OF CELL GROWTH RATES FOR INDUCTION AND TRANSFORMATION
WO2019200004A1 (en) 2018-04-13 2019-10-17 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
JP7555822B2 (ja) 2018-04-19 2024-09-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア ゲノム編集のための組成物および方法
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
US10508273B2 (en) 2018-04-24 2019-12-17 Inscripta, Inc. Methods for identifying selective binding pairs
WO2019209912A2 (en) * 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Therapeutic genome editing in x-linked hyper igm syndrome
WO2019213430A1 (en) * 2018-05-03 2019-11-07 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for nicking target dna sequences
WO2019217803A1 (en) 2018-05-10 2019-11-14 Auxolytic Ltd. Gene therapy methods and compositions using auxotrophic regulatable cells
CN112105732A (zh) * 2018-05-10 2020-12-18 先正达参股股份有限公司 用于多核苷酸的靶向编辑的方法和组合物
KR102852347B1 (ko) 2018-05-11 2025-09-01 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 아미노산을 치환하는 방법
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
GB2589246A (en) 2018-05-16 2021-05-26 Synthego Corp Methods and systems for guide RNA design and use
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
EP3575402A1 (en) * 2018-06-01 2019-12-04 Algentech SAS Gene targeting
EP3802839A1 (en) 2018-06-07 2021-04-14 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Nucleic acid constructs and methods of using same
US20210337753A1 (en) 2018-06-07 2021-11-04 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Methods of regenerating and transforming cannabis
EP4159872B1 (en) * 2018-06-25 2024-09-11 Bionano Genomics, Inc. Labeling of dna
US12338436B2 (en) 2018-06-29 2025-06-24 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
AU2019292919A1 (en) 2018-06-30 2021-03-11 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
CA3108281A1 (en) * 2018-08-03 2020-02-06 Beam Therapeutics Inc. Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence
GB201813011D0 (en) 2018-08-10 2018-09-26 Vib Vzw Means and methods for drought tolerance in crops
US10752874B2 (en) 2018-08-14 2020-08-25 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
KR102103104B1 (ko) 2018-08-16 2020-04-22 (주)라트바이오 유전자 편집된 형질전환 동물 및 형질전환 배아
US20210246472A1 (en) * 2018-08-21 2021-08-12 Sigma-Aldrich Co. Llc Down-regulation of the cytosolic dna sensor pathway
US11965154B2 (en) 2018-08-30 2024-04-23 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US12529041B2 (en) 2018-09-07 2026-01-20 Beam Therapeutics Inc. Compositions and methods for delivering a nucleobase editing system
WO2020051562A2 (en) 2018-09-07 2020-03-12 Beam Therapeutics Inc. Compositions and methods for improving base editing
CN109055379B (zh) * 2018-09-10 2022-04-15 石铭 一种转基因鸡输卵管生物反应器的制备方法
KR102121817B1 (ko) * 2018-09-12 2020-06-26 한국화학연구원 Crispr 편집 기술을 이용한 재조합 항원을 발현시키는 벡터 및 이를 동시에 다중 삽입시키는 방법
US20220053741A1 (en) 2018-09-13 2022-02-24 Regeneron Pharmaceuticals, Inc. Complement Factor H Gene Knockout Rat as a Model of C3 Glomerulopathy
US12203123B2 (en) 2018-10-01 2025-01-21 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
US12264330B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
US12264313B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression
WO2020072248A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system
WO2020076976A1 (en) 2018-10-10 2020-04-16 Readcoor, Inc. Three-dimensional spatial molecular indexing
HUE071002T2 (hu) 2018-10-16 2025-07-28 Blueallele Corp Eljárások DNS célzott beillesztésére génekbe
US12214023B2 (en) 2018-10-18 2025-02-04 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
CN113227368B (zh) 2018-10-22 2023-07-07 因思科瑞普特公司 工程化酶
US20220380740A1 (en) * 2018-10-24 2022-12-01 The Broad Institute, Inc. Constructs for improved hdr-dependent genomic editing
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
EP3894550A4 (en) 2018-12-14 2023-01-04 Pioneer Hi-Bred International, Inc. NOVEL CRISPR-CAS SYSTEMS FOR GENOME EDITING
CA3124039A1 (en) 2018-12-19 2020-06-25 King's College London Immunotherapeutic methods and compositions
IL301193A (en) 2018-12-20 2023-05-01 Regeneron Pharma Nuclease-mediated repeat expansion
EP3906042A4 (en) * 2019-01-04 2023-03-15 The University of Chicago RNA MODULATION SYSTEMS AND METHODS
WO2020146899A1 (en) * 2019-01-11 2020-07-16 Chan Zuckerberg Biohub, Inc. Targeted in vivo genome modification
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3921417A4 (en) 2019-02-04 2022-11-09 The General Hospital Corporation VARIANTS OF ADENINE DNA BASES WITH REDUCED OFF-TARGET RNA EDIT
US20220298494A1 (en) * 2019-02-14 2022-09-22 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
US10982200B2 (en) 2019-02-14 2021-04-20 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
CN113728099A (zh) * 2019-02-15 2021-11-30 西格马-奥尔德里奇有限责任公司 Crispr/cas融合蛋白和系统
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
CN113811607A (zh) 2019-03-07 2021-12-17 加利福尼亚大学董事会 CRISPR-Cas效应子多肽和其使用方法
CN113711046B (zh) 2019-03-18 2023-08-29 瑞泽恩制药公司 用于揭示与Tau聚集相关的基因脆弱性的CRISPR/Cas脱落筛选平台
SG11202108091YA (en) 2019-03-18 2021-08-30 Regeneron Pharma Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
CA3130488A1 (en) 2019-03-19 2020-09-24 David R. Liu Methods and compositions for editing nucleotide sequences
EP3947691A4 (en) 2019-03-25 2022-12-14 Inscripta, Inc. SIMULTANEOUS MULTIPLEX GENOME EDITING IN A YEAST
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
CN113727603B (zh) 2019-04-03 2024-03-19 瑞泽恩制药公司 用于将抗体编码序列插入到安全港基因座中的方法和组合物
IL286917B (en) 2019-04-04 2022-09-01 Regeneron Pharma Methods for scar-free insertion of targeted modifications into targeted vectors
EP3772929B1 (en) 2019-04-04 2023-11-15 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized coagulation factor 12 locus
GB201905360D0 (en) 2019-04-16 2019-05-29 Univ Nottingham Fungal strains, production and uses thereof
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12297440B2 (en) 2019-05-10 2025-05-13 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
JP7610339B2 (ja) 2019-06-04 2025-01-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法
CA3139122C (en) 2019-06-06 2023-04-25 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
TW202112229A (zh) 2019-06-07 2021-04-01 美商雷傑納榮製藥公司 包含人化白蛋白基因座之非人的動物
US11845957B2 (en) 2019-06-14 2023-12-19 Regeneron Pharmaceuticals, Inc. Models of tauopathy
US10907125B2 (en) 2019-06-20 2021-02-02 Inscripta, Inc. Flow through electroporation modules and instrumentation
EP3986909A4 (en) 2019-06-21 2023-08-02 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced lysine production in e. coli
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
EP3783104A1 (en) * 2019-08-20 2021-02-24 Kemijski Institut Coiled-coil mediated tethering of crispr-cas and exonucleases for enhanced genome editing
WO2021050398A1 (en) * 2019-09-10 2021-03-18 The Regents Of The University Of California Synthetic lethality screening platform for cells undergoing alt
CA3150334A1 (en) 2019-09-12 2021-03-18 Frank Meulewaeter Regulatory nucleic acid molecules for enhancing gene expression in plants
KR20220062079A (ko) 2019-09-13 2022-05-13 리제너론 파마슈티칼스 인코포레이티드 지질 나노입자에 의해 전달되는 CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
WO2021069387A1 (en) 2019-10-07 2021-04-15 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CN110628825A (zh) * 2019-10-14 2019-12-31 上海捷易生物科技有限公司 一种依赖nhej的报告基因敲入组合物及其使用方法
CN114746125B (zh) 2019-11-08 2025-08-08 瑞泽恩制药公司 用于x连锁青少年型视网膜劈裂症疗法的crispr和aav策略
WO2021102059A1 (en) 2019-11-19 2021-05-27 Inscripta, Inc. Methods for increasing observed editing in bacteria
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
WO2021110582A1 (en) 2019-12-03 2021-06-10 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
KR102776469B1 (ko) 2019-12-10 2025-03-05 인스크립타 인코포레이티드 신규 mad 뉴클레아제
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
KR20220116485A (ko) 2019-12-16 2022-08-23 바스프 아그리컬쳐럴 솔루션즈 시드 유에스 엘엘씨 쌍을 형성한 닉카제를 이용하는 개선된 게놈 편집
CN114829607A (zh) 2019-12-18 2022-07-29 因思科瑞普特公司 用于体内检测核酸引导的核酸酶编辑的细胞的Cascade/dCas3互补测定
US20230059309A1 (en) * 2020-01-09 2023-02-23 Pioneer Hi-Bred International, Inc. Two-step gene swap
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
KR20220133257A (ko) 2020-01-27 2022-10-04 인스크립타 인코포레이티드 전기천공 모듈 및 기구
KR20220133248A (ko) 2020-01-28 2022-10-04 리제너론 파마슈티칼스 인코포레이티드 인간화 pnpla3 좌위를 포함하는 비-인간 동물 및 사용 방법
EP4099821A1 (en) 2020-02-07 2022-12-14 Regeneron Pharmaceuticals, Inc. <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
JP2023515671A (ja) 2020-03-04 2023-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫療法に対する腫瘍細胞の感作のための方法及び組成物
US20230102342A1 (en) 2020-03-23 2023-03-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
MX2022012110A (es) 2020-03-31 2022-10-18 Metagenomi Inc Sistemas crispr clase ii tipo ii.
US12057197B2 (en) 2020-04-03 2024-08-06 Creyon Bio, Inc. Oligonucleotide-based machine learning
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
US20230232796A1 (en) 2020-06-26 2023-07-27 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ace2 locus
CN111849986A (zh) * 2020-07-24 2020-10-30 江苏集萃药康生物科技有限公司 一种减少CRISPR-Cas9基因编辑中双链DNA片段串联的方法及其应用
US20220049303A1 (en) 2020-08-17 2022-02-17 Readcoor, Llc Methods and systems for spatial mapping of genetic variants
EP4214314A4 (en) 2020-09-15 2024-10-16 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
US20240002839A1 (en) 2020-12-02 2024-01-04 Decibel Therapeutics, Inc. Crispr sam biosensor cell lines and methods of use thereof
WO2022133139A2 (en) * 2020-12-16 2022-06-23 Administrators Of The Tulane Educational Fund Wnt+ adipocytes, exosomes from wnt+ adipocyte, and methods of making and using them
US11306298B1 (en) 2021-01-04 2022-04-19 Inscripta, Inc. Mad nucleases
US11332742B1 (en) 2021-01-07 2022-05-17 Inscripta, Inc. Mad nucleases
BR112023014719A2 (pt) * 2021-01-22 2023-12-05 Metagenomi Inc Novas nucleases quiméricas e manipuladas
US12171813B2 (en) 2021-02-05 2024-12-24 Christiana Care Gene Editing Institute, Inc. Methods of and compositions for reducing gene expression and/or activity
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
GB202103131D0 (en) 2021-03-05 2021-04-21 Biosystems Tech Limited Method for preparation of research organisms
WO2022240846A1 (en) 2021-05-10 2022-11-17 Sqz Biotechnologies Company Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
KR20240027676A (ko) 2021-06-02 2024-03-04 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도
CA3225082A1 (en) 2021-08-27 2023-03-02 Brian C. Thomas Enzymes with ruvc domains
CA3230927A1 (en) 2021-09-10 2023-03-16 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
EP4405463A1 (en) 2021-10-14 2024-07-31 Lonza Sales AG Modified producer cells for extracellular vesicle production
EP4416292A2 (en) 2021-10-14 2024-08-21 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
EP4423271A2 (en) 2021-10-28 2024-09-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
IL312452A (en) 2021-11-01 2024-06-01 Tome Biosciences Inc A transformant has a single structure for the simultaneous transfer of a gene editing mechanism and a nucleic acid cargo
IL312505A (en) 2021-11-04 2024-07-01 Regeneron Pharma Non-human animals comprising a modified cacng1 locus
CA3234233A1 (en) 2021-11-24 2023-06-01 Brian C. Thomas Endonuclease systems
CA3238939A1 (en) 2021-12-08 2023-06-15 Gaurang Patel Mutant myocilin disease model and uses thereof
GB202118058D0 (en) 2021-12-14 2022-01-26 Univ Warwick Methods to increase yields in crops
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
WO2023122506A1 (en) 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising humanized ace2 and tmprss loci
US20250057980A1 (en) 2021-12-22 2025-02-20 Tome Biosciences, Inc. Co-Delivery of a Gene Editor Construct and a Donor Template
CN119325508A (zh) 2021-12-29 2025-01-17 百时美施贵宝公司 着陆垫细胞系的生成
WO2023150181A1 (en) 2022-02-01 2023-08-10 President And Fellows Of Harvard College Methods and compositions for treating cancer
US20250032642A1 (en) 2022-02-02 2025-01-30 Regeneron Pharmaceuticals, Inc. Crispr-mediated transgene insertion in neonatal cells
US20250194571A1 (en) 2022-02-07 2025-06-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
EP4514981A2 (en) 2022-04-29 2025-03-05 Regeneron Pharmaceuticals, Inc. Identification of tissue-specific extragenic safe harbors for gene therapy approaches
WO2023215831A1 (en) 2022-05-04 2023-11-09 Tome Biosciences, Inc. Guide rna compositions for programmable gene insertion
CN119604610A (zh) 2022-05-09 2025-03-11 瑞泽恩制药公司 用于体内抗体产生的载体和方法
KR20250027283A (ko) 2022-05-19 2025-02-25 라이엘 이뮤노파마, 인크. nr4a3을 표적하는 폴리뉴클레오타이드 및 이의 용도
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2023235726A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr interference therapeutics for c9orf72 repeat expansion disease
WO2023235725A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr-based therapeutics for c9orf72 repeat expansion disease
WO2023250384A2 (en) * 2022-06-22 2023-12-28 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
AU2023289696A1 (en) 2022-06-24 2025-01-16 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
GB2621813A (en) 2022-06-30 2024-02-28 Univ Newcastle Preventing disease recurrence in Mitochondrial replacement therapy
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
CA3261203A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. COMPOSITIONS AND METHODS OF ADMINISTRATION MEDIATED BY THE TRANSFERRIN RECEPTOR (TFR) TO THE BRAIN AND MUSCLE
EP4561348A2 (en) 2022-07-29 2025-06-04 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified transferrin receptor locus
WO2024031053A1 (en) 2022-08-05 2024-02-08 Regeneron Pharmaceuticals, Inc. Aggregation-resistant variants of tdp-43
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
EP4593872A1 (en) 2022-09-28 2025-08-06 Regeneron Pharmaceuticals, Inc. Antibody resistant modified receptors to enhance cell-based therapies
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024083579A1 (en) 2022-10-20 2024-04-25 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
WO2024098002A1 (en) 2022-11-04 2024-05-10 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
JP2025538220A (ja) 2022-11-14 2025-11-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アストロサイトへの線維芽細胞増殖因子受容体３媒介送達のための組成物および方法
JP2025538387A (ja) 2022-11-16 2025-11-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド プロテアーゼ切断可能なリンカーを有する膜結合ｉｌ－１２を含むキメラタンパク質
WO2024138194A1 (en) 2022-12-22 2024-06-27 Tome Biosciences, Inc. Platforms, compositions, and methods for in vivo programmable gene insertion
WO2024137514A1 (en) 2022-12-22 2024-06-27 Synthego Corporation Systems and method for automated oligonucleotide synthesis
IL321908A (en) 2023-01-27 2025-09-01 Regeneron Pharma Different rhabdomyovirus glycoproteins and their use
WO2024234006A1 (en) 2023-05-11 2024-11-14 Tome Biosciences, Inc. Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
WO2024259309A1 (en) 2023-06-15 2024-12-19 Regeneron Pharmaceuticals, Inc. Gene therapy for hearing disorders
AU2024309884A1 (en) 2023-06-30 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for increasing homology-directed repair
AU2024315073A1 (en) 2023-07-28 2026-01-22 Regeneron Pharmaceuticals, Inc. Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
AU2024317483A1 (en) 2023-07-28 2026-01-29 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
AU2024317508A1 (en) 2023-07-28 2026-01-29 Regeneron Pharmaceuticals, Inc. Anti-tfr: acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
WO2025038750A2 (en) 2023-08-14 2025-02-20 President And Fellows Of Harvard College Methods and compositions for treating cancer
WO2025049524A1 (en) 2023-08-28 2025-03-06 Regeneron Pharmaceuticals, Inc. Cxcr4 antibody-resistant modified receptors
WO2025050069A1 (en) 2023-09-01 2025-03-06 Tome Biosciences, Inc. Programmable gene insertion using engineered integration enzymes
GB202314578D0 (en) 2023-09-22 2023-11-08 Univ Manchester Methods of producing homoplasmic modified plants or parts thereof
WO2025122754A1 (en) 2023-12-07 2025-06-12 Regeneron Pharmaceuticals, Inc. Gaa knockout non-human animals
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
WO2025224107A1 (en) 2024-04-22 2025-10-30 Basecamp Research Ltd Method and compositions for detecting off-target editing
WO2025224182A2 (en) 2024-04-23 2025-10-30 Basecamp Research Ltd Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
WO2025235388A1 (en) 2024-05-06 2025-11-13 Regeneron Pharmaceuticals, Inc. Transgene genomic identification by nuclease-mediated long read sequencing
WO2025259669A1 (en) 2024-06-10 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for characterizing modified oligonucleotides
US20250388890A1 (en) 2024-06-20 2025-12-25 Regeneron Pharmaceuticals, Inc. ASS1 Gene Insertion For The Treatment Of Citrullinemia Type I
WO2026006542A2 (en) 2024-06-26 2026-01-02 Yale University Compositions and methods for crispr/cas9 based reactivation of human angelman syndrome

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
WO1988008450A1 (en) 1987-05-01 1988-11-03 Birdwell Finlayson Gene therapy for metabolite disorders
US5350689A (en) 1987-05-20 1994-09-27 Ciba-Geigy Corporation Zea mays plants and transgenic Zea mays plants regenerated from protoplasts or protoplast-derived cells
US5767367A (en) 1990-06-23 1998-06-16 Hoechst Aktiengesellschaft Zea mays (L.) with capability of long term, highly efficient plant regeneration including fertile transgenic maize plants having a heterologous gene, and their preparation
US7150982B2 (en) 1991-09-09 2006-12-19 Third Wave Technologies, Inc. RNA detection assays
FR2763797B1 (fr) * 1997-05-30 1999-07-16 Tabacs & Allumettes Ind Cigarette a tres faible taux de goudron presentant un gout de tabac comparable a celui d'une cigarette classique a plus fort taux de goudron
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US20020182673A1 (en) 1998-05-15 2002-12-05 Genentech, Inc. IL-17 homologous polypedies and therapeutic uses thereof
CA2361191A1 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
US8183339B1 (en) * 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2002026967A2 (en) 2000-09-25 2002-04-04 Thomas Jefferson University Targeted gene correction by single-stranded oligodeoxynucleotides
NZ540544A (en) 2000-10-27 2007-08-31 Inst Genomic Research Nucleic acids and proteins from streptococcus groups A & B
JP3454818B1 (ja) * 2001-03-16 2003-10-06 直哉 小林 肝臓細胞の増殖方法、該方法により得られる肝臓細胞、およびその用途
CA2921821A1 (en) 2001-07-12 2003-01-23 University Of Massachusetts In vivo production of small interfering rnas that mediate gene silencing
US20060253913A1 (en) 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
CA2474486C (en) 2002-01-23 2013-05-14 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
WO2003080809A2 (en) 2002-03-21 2003-10-02 Sangamo Biosciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
WO2003087993A2 (en) 2002-04-09 2003-10-23 Beattie Kenneth L Oligonucleotide probes for genosensor chips
AU2003233719A1 (en) * 2002-06-06 2003-12-22 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Modifying the dna recombination potential in eukaryotes
AU2003298574B2 (en) 2002-09-05 2008-04-24 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
DE10260805A1 (de) * 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
AU2004263865B2 (en) 2003-08-08 2007-05-17 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US8053232B2 (en) 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20050220796A1 (en) 2004-03-31 2005-10-06 Dynan William S Compositions and methods for modulating DNA repair
US7919277B2 (en) 2004-04-28 2011-04-05 Danisco A/S Detection and typing of bacterial strains
EP1833967B1 (en) * 2004-12-22 2011-04-27 Alnylam Pharmaceuticals, Inc. Conserved hbv and hcv sequences useful for gene silencing
US7892224B2 (en) 2005-06-01 2011-02-22 Brainlab Ag Inverse catheter planning
US7534819B2 (en) 2005-06-10 2009-05-19 University Of Washington Compositions and methods for intracellular delivery of biotinylated cargo
US20060282289A1 (en) 2005-06-14 2006-12-14 Healthmatch Solutions, Llc System and method for health care financing
WO2007014181A2 (en) * 2005-07-25 2007-02-01 Johns Hopkins University Site-specific modification of the human genome using custom-designed zinc finger nucleases
KR101419729B1 (ko) 2005-07-26 2014-07-17 상가모 바이오사이언스 인코포레이티드 외래 핵산 서열의 표적화된 통합 및 발현
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
EP3284833B1 (en) 2005-08-26 2021-12-01 DuPont Nutrition Biosciences ApS Use of crispr associated genes (cas)
KR100877824B1 (ko) * 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
US20100286232A1 (en) * 2006-03-02 2010-11-11 The Ohio State University Microrna expression profile associated with pancreatic cancer
US9677123B2 (en) 2006-03-15 2017-06-13 Siemens Healthcare Diagnostics Inc. Degenerate nucleobase analogs
EP2001508A2 (en) * 2006-03-28 2008-12-17 Novartis Ag Covalently-linked complexes of hiv tat and env proteins
ES2367661T3 (es) 2006-05-10 2011-11-07 Deinove Proceso de ingeniería cromosómica mediante el uso de un nuevo sistema de reparación del adn.
PL2426220T3 (pl) 2006-05-19 2017-01-31 Dupont Nutrition Biosciences Aps Wyznakowane mikroorganizmy i sposoby wyznakowania
EP2447279B1 (en) 2006-05-25 2014-04-09 Sangamo BioSciences, Inc. Methods and compositions for gene inactivation
EP2034848B1 (en) 2006-06-16 2016-10-19 DuPont Nutrition Biosciences ApS Streptococcus thermophilus bacterium
EP2054514A4 (en) * 2006-08-04 2009-11-04 Univ Georgia State Res Found ENZYME SENSORS, METHODS OF PREPARATION AND USE OF SUCH SENSORS, AND METHODS OF DETECTING PROTEASE ACTIVITY
ES2541693T3 (es) 2007-03-02 2015-07-23 Dupont Nutrition Biosciences Aps Cultivos con resistencia mejorada a fagos
GB0806086D0 (en) 2008-04-04 2008-05-14 Ulive Entpr Ltd Dendrimer polymer hybrids
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
EP2789691B1 (en) 2008-08-22 2018-08-08 Sangamo Therapeutics, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
MX2011002731A (es) 2008-09-15 2011-04-26 Childrens Medical Center Modulacion de bcl11a para tratamiento de hemoglobinopatias.
US20100076057A1 (en) * 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
WO2010054108A2 (en) 2008-11-06 2010-05-14 University Of Georgia Research Foundation, Inc. Cas6 polypeptides and methods of use
EP2362915B1 (en) 2008-11-07 2016-12-21 DuPont Nutrition Biosciences ApS Bifidobacteria crispr sequences
ES2499032T3 (es) 2008-12-12 2014-09-26 Dupont Nutrition Biosciences Aps Grupo genético de cepas de Streptococcus thermophilus que tiene propiedades reológicas únicas para fermentación láctica
WO2010075424A2 (en) 2008-12-22 2010-07-01 The Regents Of University Of California Compositions and methods for downregulating prokaryotic genes
GB0823658D0 (en) 2008-12-30 2009-02-04 Angiomed Ag Stent delivery device
US8392349B2 (en) 2009-02-23 2013-03-05 Shalini Vajjhala Global adaptation atlas and method of creating same
US9834787B2 (en) 2009-04-09 2017-12-05 Sangamo Therapeutics, Inc. Targeted integration into stem cells
CA2759438C (en) 2009-04-30 2021-03-30 Fondazione Centro San Raffaele Del Monte Tabor Gene vectors and uses thereof for preventing or reducing expression of a nucleotide sequence in a hematopoietic stem or progenitor cell but not in a differentiated cell
US20120192298A1 (en) * 2009-07-24 2012-07-26 Sigma Aldrich Co. Llc Method for genome editing
SG177711A1 (en) 2009-07-24 2012-02-28 Sigma Aldrich Co Llc Method for genome editing
CA2769262C (en) 2009-07-28 2019-04-30 Sangamo Biosciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
KR101418355B1 (ko) 2009-10-23 2014-07-11 (주)바이오니아 고밀도 유전자 합성기
DE102009052674B4 (de) 2009-11-12 2012-10-18 Karl Weinhold Verfahren und Vorrichtung zum Verbinden von Doppelmantelrohren
US20110294114A1 (en) 2009-12-04 2011-12-01 Cincinnati Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
KR102110725B1 (ko) 2009-12-10 2020-05-13 리전츠 오브 더 유니버스티 오브 미네소타 Ｔａｌ 이펙터-매개된 ｄｎａ 변형
AU2011215557B2 (en) 2010-02-09 2016-03-10 Sangamo Therapeutics, Inc. Targeted genomic modification with partially single-stranded donor molecules
US10087431B2 (en) 2010-03-10 2018-10-02 The Regents Of The University Of California Methods of generating nucleic acid fragments
CN103038338B (zh) 2010-05-10 2017-03-08 加利福尼亚大学董事会 核糖核酸内切酶组合物及其使用方法
CA2798988C (en) * 2010-05-17 2020-03-10 Sangamo Biosciences, Inc. Tal-effector (tale) dna-binding polypeptides and uses thereof
EP2392208B1 (en) * 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use
US20140148361A1 (en) 2010-06-07 2014-05-29 Barry L. Stoddard Generation and Expression of Engineered I-ONUI Endonuclease and Its Homologues and Uses Thereof
AU2011265733B2 (en) 2010-06-14 2014-04-17 Iowa State University Research Foundation, Inc. Nuclease activity of TAL effector and Foki fusion protein
SG187075A1 (en) * 2010-07-23 2013-03-28 Sigma Aldrich Co Llc Genome editing using targeting endonucleases and single-stranded nucleic acids
DK2601611T3 (da) 2010-08-02 2021-02-01 Integrated Dna Tech Inc Fremgangsmåder til forudsigelse af stabilitet og smeltetemperaturer for nukleinsyreduplekser
AU2011316980A1 (en) 2010-10-20 2013-04-18 Dupont Nutrition Biosciences Aps Lactococcus CRISPR-Cas sequences
EP2643343A1 (en) * 2010-11-26 2013-10-02 Institut Pasteur Identification of a human gyrovirus and applications.
US20120214241A1 (en) 2010-12-22 2012-08-23 Josee Laganiere Zinc finger nuclease modification of leucine rich repeat kinase 2 (lrrk2) mutant fibroblasts and ipscs
KR20120096395A (ko) 2011-02-22 2012-08-30 주식회사 툴젠 뉴클레아제에 의해 유전자 변형된 세포를 농축시키는 방법
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
AU2012312260B2 (en) 2011-09-21 2017-08-31 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
HK1200871A1 (en) * 2011-11-16 2015-08-14 Sangamo Therapeutics, Inc. Modified dna-binding proteins and uses thereof
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
KR101833589B1 (ko) 2012-02-24 2018-03-02 프레드 헛친슨 켄서 리서치 센터 이상혈색소증 치료를 위한 조성물 및 방법
MX374399B (es) 2012-02-29 2025-03-06 Sangamo Biosciences Inc Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
AU2013204327B2 (en) 2012-04-20 2016-09-01 Aviagen Cell transfection method
EP2841581B2 (en) 2012-04-23 2023-03-08 BASF Agricultural Solutions Seed US LLC Targeted genome engineering in plants
CA2869016C (en) 2012-04-25 2020-05-05 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
NZ701060A (en) 2012-05-02 2016-10-28 Sangamo Biosciences Inc Targeted modification of malate dehydrogenase
JP6559063B2 (ja) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物
US11120889B2 (en) 2012-05-09 2021-09-14 Georgia Tech Research Corporation Method for synthesizing a nuclease with reduced off-site cleavage
EP4570908A3 (en) * 2012-05-25 2025-10-22 The Regents of the University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
KR20150027756A (ko) 2012-05-30 2015-03-12 베일러 칼리지 오브 메디신 Dna 수복, 변경 및 대체를 위한 도구로서의 초나선 미니벡터
US9102936B2 (en) 2012-06-11 2015-08-11 Agilent Technologies, Inc. Method of adaptor-dimer subtraction using a CRISPR CAS6 protein
US20150128300A1 (en) 2012-06-12 2015-05-07 Genentech, Inc. Methods and compositions for generating conditional knock-out alleles
EP2674501A1 (en) 2012-06-14 2013-12-18 Agence nationale de sécurité sanitaire de l'alimentation,de l'environnement et du travail Method for detecting and identifying enterohemorrhagic Escherichia coli
US9688971B2 (en) 2012-06-15 2017-06-27 The Regents Of The University Of California Endoribonuclease and methods of use thereof
BR112014031891A2 (pt) 2012-06-19 2017-08-01 Univ Minnesota direcionamento genético nas plantas utilizando vírus de dna
JP6329537B2 (ja) 2012-07-11 2018-05-23 サンガモ セラピューティクス， インコーポレイテッド 生物学的薬剤の送達のための方法および組成物
ES2813080T3 (es) 2012-07-11 2021-03-22 Sangamo Therapeutics Inc Métodos y composiciones para el tratamiento de enfermedades por almacenamiento lisosomal
ES2757623T3 (es) 2012-07-25 2020-04-29 Broad Inst Inc Proteínas de unión a ADN inducibles y herramientas de perturbación genómica y aplicaciones de las mismas
HK1207111A1 (en) 2012-08-03 2016-01-22 加利福尼亚大学董事会 Methods and compositions for controlling gene expression by rna processing
DK2890780T3 (da) 2012-08-29 2020-09-21 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
EP3406715B1 (en) 2012-09-07 2023-12-13 Corteva Agriscience LLC Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
UA118090C2 (uk) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
UA119135C2 (uk) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб отримання трансгенної рослини
EP3789405A1 (en) 2012-10-12 2021-03-10 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
CN116064532A (zh) * 2012-10-23 2023-05-05 基因工具股份有限公司 用于切割靶dna的组合物及其用途
BR112015009589A2 (pt) 2012-10-30 2017-11-14 Recombinetics Inc processos de produção de um animal de produção não humano, animal de produção geneticamente modificado não humano, organismo in vitro não humano escolhido do grupo que consiste em uma célula ou um animal blastocisto, o organismo in vitro, processo de produção de uma célula de animal de produção geneticamente modificado não humano, animal de produção não humano e método de produção de um animal de produção geneticamente modificado não humano
BR112015009812A2 (pt) 2012-10-31 2017-08-22 Cellectis Método para a inserção genética específica em um genoma de planta, célula de planta transformada e seu uso, planta resistente a herbicidas, kit, vetor, e célula hospedeira
US20140127752A1 (en) 2012-11-07 2014-05-08 Zhaohui Zhou Method, composition, and reagent kit for targeted genomic enrichment
SG11201503824SA (en) 2012-12-06 2015-06-29 Sigma Aldrich Co Llc Crispr-based genome modification and regulation
WO2014093479A1 (en) 2012-12-11 2014-06-19 Montana State University Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
DK3064585T3 (da) 2012-12-12 2020-04-27 Broad Inst Inc Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation
EP2784162B1 (en) 2012-12-12 2015-04-08 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
WO2014093595A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
PT2784162E (pt) 2012-12-12 2015-08-27 Broad Inst Inc Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014093622A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
EP2931892B1 (en) 2012-12-12 2018-09-12 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
RU2678001C2 (ru) 2012-12-13 2019-01-22 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Способы обнаружения днк для сайт-специфической нуклеазной активности
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
EP2938184B1 (en) 2012-12-27 2018-10-31 Keygene N.V. Method for removing genetic linkage in a plant
US10544405B2 (en) 2013-01-16 2020-01-28 Emory University Cas9-nucleic acid complexes and uses related thereto
CN103233028B (zh) 2013-01-25 2015-05-13 南京徇齐生物技术有限公司 一种无物种限制无生物安全性问题的真核生物基因打靶方法及螺旋结构dna序列
WO2014127287A1 (en) 2013-02-14 2014-08-21 Massachusetts Institute Of Technology Method for in vivo tergated mutagenesis
CN109913495B (zh) 2013-02-20 2022-11-25 瑞泽恩制药公司 大鼠的遗传修饰
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
EP2971167B1 (en) 2013-03-14 2019-07-31 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US20140364333A1 (en) 2013-03-15 2014-12-11 President And Fellows Of Harvard College Methods for Live Imaging of Cells
KR102405549B1 (ko) 2013-03-15 2022-06-08 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
MX376838B (es) 2013-03-15 2025-03-07 Univ Minnesota Ingenieria genomica de plantas utilizando sistemas crispr/cas.
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
CN105518146B (zh) 2013-04-04 2022-07-15 哈佛学院校长同事会 利用CRISPR/Cas系统的基因组编辑的治疗性用途
KR102192599B1 (ko) 2013-04-05 2020-12-18 다우 아그로사이언시즈 엘엘씨 식물의 게놈 내의 외인성 서열의 통합을 위한 방법 및 조성물
SMT202100516T1 (it) 2013-04-16 2021-11-12 Regeneron Pharma Modificazione mirata del genoma di ratto
CN103224947B (zh) 2013-04-28 2015-06-10 陕西师范大学 一种基因打靶系统
EP2994531B1 (en) 2013-05-10 2018-03-28 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US20140349405A1 (en) 2013-05-22 2014-11-27 Wisconsin Alumni Research Foundation Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
US11414695B2 (en) 2013-05-29 2022-08-16 Agilent Technologies, Inc. Nucleic acid enrichment using Cas9
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
WO2014204725A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
KR20160019553A (ko) 2013-06-17 2016-02-19 더 브로드 인스티튜트, 인코퍼레이티드 유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
WO2014204729A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
EP3725885A1 (en) 2013-06-17 2020-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
RU2716420C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
CN103343120B (zh) 2013-07-04 2015-03-04 中国科学院遗传与发育生物学研究所 一种小麦基因组定点改造方法
CN103382468B (zh) * 2013-07-04 2015-04-29 中国科学院遗传与发育生物学研究所 一种水稻基因组定点改造方法
WO2015006294A2 (en) 2013-07-10 2015-01-15 President And Fellows Of Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
CN103388006B (zh) 2013-07-26 2015-10-28 华东师范大学 一种基因定点突变的构建方法
US10421957B2 (en) 2013-07-29 2019-09-24 Agilent Technologies, Inc. DNA assembly using an RNA-programmable nickase
NZ735257A (en) 2013-11-04 2018-09-28 Dow Agrosciences Llc Optimal soybean loci
JP6634022B2 (ja) 2013-11-04 2020-01-22 ダウ アグロサイエンシィズ エルエルシー 最適なダイズ遺伝子座
BR102014027438B1 (pt) 2013-11-04 2022-09-27 Dow Agrosciences Llc Molécula de ácido nucleico recombinante e método de produção de uma célula vegetal transgênica
ES2670983T3 (es) 2013-11-07 2018-06-04 Editas Medicine, Inc. Métodos y composiciones relacionados con CRISPR con ARNg rectores
BR112016013400B1 (pt) 2013-12-11 2023-02-14 Regeneron Pharmaceuticals, Inc. Método in vitro para modificar um genoma em um lócus genômico de interesse em uma célula pluripotente
WO2015116686A1 (en) 2014-01-29 2015-08-06 Agilent Technologies, Inc. Cas9-based isothermal method of detection of specific dna sequence
US20150291969A1 (en) 2014-01-30 2015-10-15 Chromatin, Inc. Compositions for reduced lignin content in sorghum and improving cell wall digestibility, and methods of making the same
US20150225801A1 (en) 2014-02-11 2015-08-13 California Institute Of Technology Recording and mapping lineage information and molecular events in individual cells
WO2015127439A1 (en) 2014-02-24 2015-08-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration
EP3929279A1 (en) 2014-03-18 2021-12-29 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression

Also Published As

Publication number Publication date
CA2891347C (en) 2018-02-27
KR20180011351A (ko) 2018-01-31
IL300199B2 (en) 2025-07-01
AU2017204031B2 (en) 2018-06-14
PL3138911T3 (pl) 2019-04-30
EP2928496B1 (en) 2019-10-09
SG10201910987SA (en) 2020-01-30
AU2019201344C1 (en) 2020-12-24
AU2013355214A1 (en) 2015-06-04
US20160298132A1 (en) 2016-10-13
AU2023216829A1 (en) 2023-09-14
PL3363902T3 (pl) 2020-05-18
EP3138912B1 (en) 2018-12-05
KR20230003624A (ko) 2023-01-06
PL2928496T3 (pl) 2020-04-30
IL291129B2 (en) 2023-07-01
WO2014089290A1 (en) 2014-06-12
HK1218389A1 (zh) 2017-02-17
DK3138911T3 (en) 2019-01-21
DK3363902T3 (da) 2020-01-02
IL257178B (en) 2019-07-31
IL291129A (en) 2022-05-01
US20160298133A1 (en) 2016-10-13
AU2020273316A1 (en) 2020-12-17
US20160298134A1 (en) 2016-10-13
PT3138911T (pt) 2018-12-28
DK3360964T3 (da) 2019-10-28
JP7478772B2 (ja) 2024-05-07
KR20200098727A (ko) 2020-08-20
US20160298135A1 (en) 2016-10-13
US20160298138A1 (en) 2016-10-13
CN105142669A (zh) 2015-12-09
IL238856B (en) 2018-03-29
AU2023216829B2 (en) 2025-10-09
KR102531576B1 (ko) 2023-05-11
CN108913676A (zh) 2018-11-30
ES2757325T3 (es) 2020-04-28
CA3034794A1 (en) 2014-06-12
SG10201800585VA (en) 2018-02-27
SG10202107423UA (en) 2021-08-30
DK3138910T3 (en) 2017-10-16
IL291129B1 (en) 2023-03-01
PL3138910T3 (pl) 2018-01-31
IL238856A0 (en) 2015-06-30
EP3138912A1 (en) 2017-03-08
LT3363902T (lt) 2020-02-10
JP2016502840A (ja) 2016-02-01
EP3138909A1 (en) 2017-03-08
KR20210045515A (ko) 2021-04-26
EP3360964A1 (en) 2018-08-15
SG11201503824SA (en) 2015-06-29
US20170191082A1 (en) 2017-07-06
AU2022200330B2 (en) 2023-11-09
CN108715602A (zh) 2018-10-30
KR102006880B1 (ko) 2019-08-02
EP3138910A1 (en) 2017-03-08
AU2022200330A1 (en) 2022-02-17
PT3360964T (pt) 2019-10-29
KR20150091052A (ko) 2015-08-07
CN105142669B (zh) 2018-07-03
PT3138910T (pt) 2017-10-18
AU2018229489B2 (en) 2018-12-06
DK2928496T3 (da) 2019-11-11
ES2713243T3 (es) 2019-05-20
LT3138910T (lt) 2017-11-10
IL300199A (en) 2023-03-01
AU2020273316B2 (en) 2023-05-18
US20170073705A1 (en) 2017-03-16
KR20190093680A (ko) 2019-08-09
JP2017192392A (ja) 2017-10-26
EP3363902B1 (en) 2019-11-27
PL3360964T3 (pl) 2020-03-31
KR102676910B1 (ko) 2024-06-19
EP2928496A4 (en) 2017-03-01
EP3138911B1 (en) 2018-12-05
US20160298137A1 (en) 2016-10-13
AU2013355214B2 (en) 2017-06-15
LT3138912T (lt) 2019-02-25
CA2977152C (en) 2019-04-09
DK3138912T3 (en) 2019-01-21
AU2020230243B2 (en) 2021-10-21
AU2018229489A1 (en) 2018-10-04
CA2977152A1 (en) 2014-06-12
BR112015012375A2 (pt) 2017-09-26
IL300199B1 (en) 2025-03-01
JP2022115994A (ja) 2022-08-09
ES2769310T3 (es) 2020-06-25
KR20230070065A (ko) 2023-05-19
US20160298125A1 (en) 2016-10-13
EP3360964B1 (en) 2019-10-02
PT2928496T (pt) 2019-11-11
IL267598A (en) 2019-08-29
US20160298136A1 (en) 2016-10-13
AU2019201344B2 (en) 2020-09-03
ES2714154T3 (es) 2019-05-27
EP2928496A1 (en) 2015-10-14
EP3363902A1 (en) 2018-08-22
IL267598B (en) 2022-05-01
KR102145760B1 (ko) 2020-08-19
ES2757808T3 (es) 2020-04-30
EP3617309A3 (en) 2020-05-06
JP2021101706A (ja) 2021-07-15
EP3611263A1 (en) 2020-02-19
US20210207173A1 (en) 2021-07-08
ES2653212T3 (es) 2018-02-06
CA2891347A1 (en) 2014-06-12
PL3138912T3 (pl) 2019-04-30
CN108913676B (zh) 2023-11-03
US20210388396A1 (en) 2021-12-16
US20210079427A1 (en) 2021-03-18
LT3138911T (lt) 2019-02-25
AU2017204031A1 (en) 2017-07-06
JP2019037231A (ja) 2019-03-14
US20200140897A1 (en) 2020-05-07
EP3617309A2 (en) 2020-03-04
AU2020230246B2 (en) 2020-11-05
PT3138912T (pt) 2018-12-28
KR101844123B1 (ko) 2018-04-02
IL257178A (en) 2018-03-29
EP3138911A1 (en) 2017-03-08
EP3135765A1 (en) 2017-03-01
EP3141604A1 (en) 2017-03-15
US10731181B2 (en) 2020-08-04
US20160017366A1 (en) 2016-01-21
EP3138910B1 (en) 2017-09-20
US10745716B2 (en) 2020-08-18
AU2019201344A1 (en) 2019-03-21
JP2020120674A (ja) 2020-08-13
AU2020230246A1 (en) 2020-10-01
KR102243092B1 (ko) 2021-04-22
KR102479178B1 (ko) 2022-12-19
AU2020230243A1 (en) 2020-10-01
PT3363902T (pt) 2019-12-19

Similar Documents

Publication Publication Date Title
JP7478772B2 (ja) Ｃｒｉｓｐｒに基づくゲノム修飾および制御
HK1218389B (zh) 基於crispr的基因组修饰和调控

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180529

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191118

R150 Certificate of patent or registration of utility model

Ref document number: 6620018

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250